Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted

Recently, CGeneTech (Suzhou) Co., Ltd. (CGeneTech) submitted the DPP-4 inhibitor Sitagliptin, for the treatment of type 2 diabetes, to the National Medical Products Administration (NMPA) for approval.

Medicilon helped CGeneTech submit the DPP-4 inhibitor Sitagliptin.webp

Shanghai Medicilon Inc. (Medicilon), as a partner of CGeneTech, provided Sitagliptin with comprehensive preclinical research services in compliance with GLP regulations, including pharmacodynamic research, pharmacokinetic research and safety evaluation, as well as Phase I clinical bioanalysis to facilitate its efficient and high-quality R&D.

Medicilon Preclinical Research Platform

Help drug research and development faster, better and cost-efficient

Efficiency comes from collaboration, and success comes from experience. Medicilon, as a one-stop comprehensive preclinical research and development service CRO for biopharmaceutical, has been continuously improving the scientific and technological innovation for 19 years, providing customized preclinical test service solutions for various drugs, and have accumulated rich R&D experience in drug metabolism, pharmacokinetics, pharmacodynamics research, and toxicology. With high-quality data and fast turnaround time, Medicilon preclinical research platform could help clients to develop their drugs faster, better and with less cost.

As early as 2009, the preclinical research laboratory of Medicilon's wholly-owned subsidiary, Medicilon Preclinical Research (Shanghai) LLC, obtained the certification of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and reached the GLP standard of both US FDA and China’s NMPA, as well as the preclinical safety evaluation with the GLP specification of the Organization for European Economic Cooperation and Development (OECD).

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

Shanghai Medicilon Inc.

搜索此博客